Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod
HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.
HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.
Aurobindo Pharma, an Indian maker of generic pharmaceuticals and active pharmaceutical ingredients, announced it signed a voluntary sub-licensing with a UN body for.